ClinicalTrials.gg

Program

direclidine

Also written as “NBI-1117568”, “HTL0016878” and “HTL0016878.HCl Solution 10 mg”.

Its studies are mostly in Schizophrenia · Mania, led by 2 companies.

Furthest: phase 3, since Apr 30, 20259 company-led studies, 5 open or runningNext primary completion: Oct 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Neurocrine Biosciences65 open or runningphase 3since Apr 30, 2025Sep 14, 2022Oct 2027phase 3 · NCT06963034
Nxera Pharma UK30 open or runningphase 1since Aug 3, 2017Aug 3, 2017none ahead

Also a collaborator on its studies: AbbVie.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 3, 2017First study: phase 1 study in HealthyNew to Nxera Pharma UKNxera Pharma UK · NCT03244228 · 120 enrolled · United Kingdom
  2. Apr 15, 2021Phase 1 study in Healthy SubjectsNxera Pharma UK · NCT04849286 · 16 enrolled · United Kingdom
  3. Jun 21, 2021Phase 1 study in Healthy SubjectsNxera Pharma UK · NCT04935320 · 15 enrolled · United Kingdom
  4. Sep 14, 2022Neurocrine Biosciences's first study: phase 2 study in SchizophreniaNew to Neurocrine BiosciencesNeurocrine Biosciences · NCT05545111 · 210 enrolled · United States
  5. Apr 30, 2025Phase 3 study in SchizophreniaNeurocrine Biosciences · NCT06963034 · 284 planned · United States
  6. Jul 29, 20252 phase 3 studies in SchizophreniaNeurocrine Biosciences · NCT07114874, NCT07105098
  7. Nov 11, 2025Phase 3 study in SchizophreniaNeurocrine Biosciences · NCT07227818 · 560 planned · United States, Puerto Rico, Serbia
  8. Dec 15, 2025Phase 2 study in ManiaNeurocrine Biosciences · NCT07288320 · 150 planned · United States

Ahead

  1. Oct 2027Primary completion: phase 3 study in SchizophreniaNeurocrine Biosciences · NCT06963034
  2. Nov 2027Primary completion: phase 3 study in SchizophreniaNeurocrine Biosciences · NCT07105098
  3. Feb 2028Primary completion: phase 2 study in ManiaNeurocrine Biosciences · NCT07288320
  4. Jul 2029Primary completion: phase 3 study in SchizophreniaNeurocrine Biosciences · NCT07227818

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 9 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07288320Mania · United States2RecruitingNeurocrine BiosciencesFeb 2028150
NCT07227818Schizophrenia · United States, Puerto Rico, Serbia3RecruitingNeurocrine BiosciencesJul 2029560
NCT07114874Schizophrenia · United States, Bulgaria, Puerto Rico and more3RecruitingNeurocrine BiosciencesDec 2031600
NCT07105098Schizophrenia · United States, Bulgaria, Hungary and more3RecruitingNeurocrine BiosciencesNov 2027284
NCT06963034Schizophrenia · United States3RecruitingNeurocrine BiosciencesOct 2027284
NCT05545111Schizophrenia · United States2CompletedNeurocrine BiosciencesJul 10, 2024210
NCT04935320Healthy Subjects · United Kingdom1CompletedNxera Pharma UKOct 29, 202115
NCT04849286Healthy Subjects · United Kingdom1CompletedNxera Pharma UKDec 7, 201816
NCT03244228Healthy · United Kingdom1CompletedNxera Pharma UKSep 23, 2019120

How it is read

Names in the registry

  • “NBI-1117568”, 6 entries
  • “HTL0016878”, 2 entries
  • “HTL0016878.HCl Solution 10 mg”, 1 entry
  • “HTL0016878.Citrate Capsule 10 mg”, 1 entry

Codes read as this program: HTL0016878.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.
direclidine (Neurocrine Biosciences): development program | ClinicalTrials.gg